Frequency of Functional and Non-Functional Pituitary Adenomas in Patients Presented at Ayub Teaching Hospital, Abbottabad


  • Abdul Aziz Khan Ayub Medical Complex and Teaching Hospital, Abbottabad, Pakistan
  • Junaid Alam Ayub Medical Complex and Teaching Hospital, Abbottabad, Pakistan
  • Muhammad Irfan-ud-Din
  • Nisar Ahmad
  • Muhammad Idrees
  • Waseef Ullah



Functional/Non-functional Adenoma, Pituitary Adenomas


Objective:  Pituitary lesions cause morbidity and mortality in all age groups due to their hormonal hypersecretion, its mass effects, and post-surgery complications. The present study determined the frequency of functional and non-functional pituitary adenomas.

Materials & Methods:  The study included patients (n = 114) presenting with functional and non-functional pituitary adenoma. Pituitary adenomas were diagnosed based on MRI brain with contrast and the size of the tumor was noted a tumor having a size of 10 mm or more was labeled as macro adenoma and a tumor having a size less than 10 mm was labeled as microadenoma. Pituitary adenomas were stratified among age, gender, duration of symptoms, types of adenomas, types of functional adenoma, and type of the tumor on a size basis.

Results:  Most of the patients had TSH- secreting adenoma (21.9%). 52.6% were found with microadenoma and 47.4% had macro adenoma. Patients with functional adenoma were 30.7% and with non-functional adenoma 32.5% were male while patients with functional adenoma were 26.3% and with non-functional adenoma 10.5%were female (p = 0.018). Patients with functional adenoma (43.9%) and non-functional adenoma (8.8%) were found to have microadenoma, whereas patients with functional adenoma (13.2%) and non-functional adenoma (34.2%) were found to have macroadenoma (p = 0.000). Patients with functional adenoma having a duration of symptoms below 1 year were 11 (9.6%), 1 to 3 years were 25 (21.9%), 17 (14.9%) were 4 to 6 years, and 12 (10.5%) above 6 years duration of symptoms.

Conclusion:  Patients with pituitary adenomas should be diagnosed early to receive successful therapy.


Hong GK, Payne SC, Jane JA. Anatomy, physiology, and laboratory evaluation of the pituitary gland. Otolaryngol Clin North Am. 2016; 49 (1): 21-32.

Inoshita N, Nishioka H. The 2017 WHO classification of pituitary adenoma: overview and comments. Brain Tumor Pathol. 2018; 35 (2): 51-6.

Yamanaka R, Abe E, Sato T, Hayano A, Takashima Y. Secondary intracranial tumors following radiotherapy for pituitary adenomas: A systematic review. Cancers (Basel), 2017; 9 (8): 1–16.

Day PF, Loto MG, Glerean M, Picasso MFR, Lovazzano S, Giunta DH. Incidence and prevalence of clinically relevant pituitary adenomas: retrospective cohort study in a Health Management Organization in Buenos Aires, Argentina. Arch Endocrinol Metab. 2016; 60: 554–61.

Rane S, Kavatkar A, Pathan A, Puranik S. Pituitary adenoma: a short illustrative review. Indian J Neurosurg. 2016; 5 (03): 180-2.

Vroomen L, Daly AF, Beckets A. Epidemiology and management challenges in prolectinomas. Neuroendocrinology, 2019; 109 (1): 20-27.

Molitch ME. Diagnosis and treatment of pituitary adenomas: a review. J Am Med Assoc. 2017; 317 (5): 516-24.

Theodros D, Patel M, Ruzevick J, Lim M, Bettegowda C. Pituitary adenomas: historical perspective, surgical management and future directions. CNS Oncol. 2015; 4 (6): 411-29.

Ntali G, Wass JA. Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas. Pituitary, 2018; 21 (2): 111-8.

Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metabol. 2006; 91 (12): 4769-75.

Saeger W, Honegger J, Theodoropoulou M, Knappe UJ, Schöfl C, Petersenn S, Buslei R. Clinical impact of the current WHO classification of pituitary adenomas. Endocr Pathol. 2016; 27 (2): 104-14.

Chanson P, Salenave S. Diagnosis and treatment of pituitary adenomas. Minerva Endocrinol. 2004; 29 (4): 241-75.

Di Ieva A, Rotondo F, Syro LV, Cusimano MD, Kovacs K. Aggressive pituitary adenomas—diagnosis and emerging treatments. Nat Rev Endocrinol. 2014; 10 (7): 423.

Karavitaki N. Prevalence and incidence of pituitary adenomas. In Annales d'endocrinologie, 2012 Apr. 1 (Vol. 73, No. 2, pp. 79-80). Elsevier Masson.

Chin SO. Epidemiology of functioning pituitary adenomas. Endocrinology and Metabolism, 2020; 35 (2): 237-42.

Di Somma C, Scarano E, de Alteriis G, Barrea L, Riccio E, Arianna R, Savastano S, Colao A. Is there any gender difference in epidemiology, clinical presentation and co-morbidities of non-functioning pituitary adenomas? A prospective survey of a National Referral Center and review of the literature. Journal of Endocrinological Investigation, 2021; 44 (5): 957-68.

Mindermann T, Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clinical Endocrinology, 1994; 41 (3): 359-64.

Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clinical Endocrinology, 1998; 48 (5): 547-53.